Did you know?
ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.
Free Newsletter
Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!
Free Report
For better result, minimum character length is four(4)
CBT 200 Loses 41 Points. More details...
While an Influenza Pandemic Is On Everyone's Mind. More...
Doing More With Monoclonal Antibodies. More details...
CBT 200 Adds 27 Points. More details...
A List Of Players To Watch. More details...
The CBT 200 Drops 62 Points. More details...
CBT 200 Rises 39 Points. More details...
Novartis Strengthens Its Vaccine Position. More details...
Bush Proposes Avian Flu Plan. More details...
CBT Slips 11 Points. More details...
ChinaBio® News
Greg Scott Interviewed at BIO-Europe Spring
How to bring your China assets to China in 8 minutes
"Mr. Bio in China."
Mendelspod Interview
Multinational pharma held to a higher standard in China